PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma

NCT05466474 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Melanoma

Interventions

BIOLOGICAL: Tislelizumab Injection

Sponsor

Henan Cancer Hospital